Skip Ribbon Commands
Skip to main content
Clin Asst Prof Chan Junjie Jack

Clin Asst Prof Chan Junjie Jack

MBBS, MRCP (UK), M Med (Internal Medicine), FAMS


National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Breast, Gynae-Oncology

Conditions Treated by this Doctor:
Breast Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer.

Clinical Appointments

  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Department of Gynaecological Oncology KK Women's and Children's HospitalKK Women's and Children's Hospital

Academic Appointments

  • Clincial Assistant Prof SingHealth Duke-NUS Oncology Academic Clinical Programme
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore


Dr Jack Chan is a Consultant Medical Oncologist who practises at NCCS and KKWCH. He completed his specialist training at NCCS, and is a Fellow of the Academy of Medicine, Singapore. He did a fellowship in early drug development and translational medicine in gynaecological cancers at Cancer Research UK Edinburgh Centre and Edinburgh Cancer Centre under the Health Manpower Development Plan Award.

Dr Chan's subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in these cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020, Star 2022).

Dr Chan believes in taking a personalised approach to cancer care. He strives to support patients and their families through navigating the cancer journey by addressing patients' medical needs and quality of life.


  • Fellow of Academy of Medicine Singapore, Chapter of Medical Oncologists, College of Physicians, 2018
  • Member of Royal College of Physicians (UK); Master of Medicine (Internal Medicine) (Singapore), 2012
  • Bachelor of Medicine and Bachelor of Surgery, 2008

Professional Appointments and Committee Memberships

· Member, Young College of Physicians Committee, College of Physicians, Academy of Medicine Singapore
· Member, Pharmacy Cost Review Workgroup, NCCS
· Executive Committee Member, Singapore General Hospital (SGH) Campus, Institution Junior Doctors Well-being Committee
· Co-Chairperson, Resource Optimisation Workgroup, NCCS
· Member, Cancer Education and Information Service Advisory Committee, NCCS
· Co-Chairperson, Breast Cancer Awareness Month Committee, NCCS
Clinical Core Faculty Member, SingHealth Medical Oncology Residency Programme


  • Singapore Health Quality Service Star Award, 2022SingHealth Family Target Zero Harm Team Award, 2021
  • Singapore Health Quality Service Hero Award, 2021
  • Residency in SingHealth Excels Outstanding Faculty Award, 2020
  • Singapore Health Quality Service Gold Award, 2020
  • Health Manpower Development Plan Award, 2019
  • Singapore Health Quality Service Silver Award, 2019

Research Interests


  • Loo SY, Toh LP, Xie WH, Pathak E, Tan W, Ma S, Lee MY, Shatishwaran S, JZZ Yeo, Yuan J, Ho YY, EKL Peh, Muniandy M, Torta F, Chan J, Tan T, Sim YR, Tan V, Tan B, Madhukumar P, Yong WS, Ong KW, Wong CY, Tan PH, Yap YS, Deng LW, Dent R, Foo R, Wenk MR, Lee SC, Ho YS, Lim EH. Fatty Acid Oxidation is a Druggable Gateway Regulating Cellular Plasticity for Driving Metastasis in Breast Cancer. Sci Adv 2021; 7(41): eabh2443.
  • Tan TJ, Chan JJ, Dent RA. Immunotherapy as Maintenance Treatment in Metastatic Triple Negative Breast Cancer. J Cancer Metastasis Treat 2021; 7:21.
  • Tan DSP, Chan JJ, Hettle R, Ghosh W, Viswambaram A, Yu CC. Cost-effectiveness of Olaparib versus Routine Surveillance in the Maintenance Setting for Patients with BRCA-mutated Advanced Ovarian Cancer After Response to First-line Platinum-based Chemotherapy in Singapore. J Gynecol Oncol 2021; 32(2):e27.
  • Kwek JW, Chan JJ, Kanesvaran R, Wang MLC, Neo PSH, Chia CS, Tham CK, Chew LST, Tan HK, Yap SP, Dent RA, Hwang WYK, Lim ST. Early Outcomes of a National Cancer Center's Strategy Against COVID-19 Executed Through a Disease Outbreak Response Taskforce. JCO Oncol Practice 2021; 17(3):e343-e54.
  • Ng DQ, Tan CJ, Soh BC, Tan MML, Loh S, Tan YE, Ong HH, Teng PPC, Chan JJ, Chay WY, Lee J, Lai GGY, Beh SY, Tan T, Yap YS, Lee GE, Wong M, Dent R, Lo Y, Chan A, Loh KW. Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. Front Neurol 2020; 11:604688.
  • Chan JJ, Tan TJY, Dent RA. Integrating Immunotherapy in the (Neo)adjuvant Setting of Early Breast Cancer. Curr Opin Oncol 2020; 32(6):575-84.
  • Chan JJ, Sim Y, Ow SGW, Lim JSJ, Kusumawidjaja G, Zhuang Q, Wong RX, Wong FY, Tan VKM, Tan TJY. The Impact of COVID-19 on and Recommendations for Breast Cancer Care: the Singapore Experience. Endocr Relat Cancer 2020; 27(9):R307-27.
  • Chan JJ, Tan TJY, Dent RA. Novel Therapeutic Avenues in Triple Negative Breast Cancer: PI3K/AKT inhibition, Androgen Receptor Blockade, and Beyond. Ther Adv Med Oncol 2019; 11:1758835919880429.
  • Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiol 2019; 56(7):4741-50.
  • Chan JJ, Tan TJY, Dent RA. Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018? J Oncol Pract 2018; 14(5):281-9.
  • Tan TJ, Chan JJ, Kamis S, Dent R. What is the Role of Immunotherapy in Breast Cancer. Chin Clin Oncol 2018; 7(2):13.

Research Trials

  • Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) ( Identifier: NCT04620954) (Principal Investigator

  • Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01) ( Identifier: NCT03100006) (Principal Investigator)